Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 10.24M | 15.99M | 18.64M | 17.38M | 20.43M |
| Total Depreciation and Amortization | 1.78M | 1.66M | 1.55M | 1.45M | 1.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 462.00K | 561.00K | 340.00K | 2.97M | -945.00K |
| Change in Net Operating Assets | -7.60M | -12.26M | -16.10M | -8.30M | 484.00K |
| Cash from Operations | 4.88M | 5.95M | 4.43M | 13.50M | 21.41M |
| Capital Expenditure | -303.00K | -275.00K | -321.00K | -292.00K | -260.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 5.80M | 5.80M | 5.80M | -- | -- |
| Other Investing Activities | -497.00K | -497.00K | -494.00K | -- | -- |
| Cash from Investing | 5.00M | 5.03M | 4.99M | -292.00K | -260.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.00K | -6.00K | -9.00K | -12.00K | -12.00K |
| Issuance of Common Stock | 813.00K | 769.00K | 4.24M | 7.25M | 10.81M |
| Repurchase of Common Stock | -5.37M | -5.37M | -2.61M | -251.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102.00K | -102.00K | -108.00K | -67.00K | -53.00K |
| Cash from Financing | -4.66M | -4.71M | 1.52M | 6.92M | 10.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.22M | 6.27M | 10.93M | 20.13M | 31.89M |